Denali Therapeutics (DNLI) vs Dianthus Therapeutics (DNTH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Dianthus Therapeutics (DNTH) has outperformed Denali Therapeutics (DNLI) over the past year, gaining 144.6% versus a gain of 28.6%. Over five years, DNTH leads with a -21.2% price change compared with -57.9% for DNLI. Dianthus Therapeutics is the larger company by market cap ($4.63 billion vs $2.98 billion), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNLI | DNTH |
|---|---|---|
| Share price | $18.67 | $82.86 |
| Market cap | $2.98B | $4.63B |
| 1-day change | -2.58% | -2.38% |
| YTD return | +16.05% | +105.97% |
| 1-year return | +28.59% | +144.61% |
| 5-year return | -57.95% | -21.17% |
| EPS (TTM) | $-2.84 | $-4.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $2.04M |
| Revenue growth (YoY) | — | -67.35% |
| Net income (latest FY) | $-512.54M | $-162.34M |
| Operating margin | — | -8739.34% |
| Net margin | — | -7973.33% |
| 52-week high | $27.30 | $117.88 |
| 52-week low | $13.75 | $32.22 |
| Distance from 52-week high | -31.63% | -29.71% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +93.20% | +69.93% |
| Average volume | 1.61M | 821.22K |
| Shares outstanding | 159.85M | 55.93M |
| Employees | 503 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNTH has outperformed DNLI by 116.0 percentage points over the past year.
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
DNLI vs DNTH FAQ
Which is bigger, Denali Therapeutics or Dianthus Therapeutics?
Dianthus Therapeutics (DNTH) is larger, with a market capitalization of $4.63B compared with $2.98B for Denali Therapeutics (DNLI).
Which stock has performed better over the past year, DNLI or DNTH?
DNTH returned +144.61% over the past 12 months, compared with +28.59% for DNLI (price return, excluding dividends). Past performance does not predict future results.
Are Denali Therapeutics and Dianthus Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Denali Therapeutics and Biotechnology: Pharmaceutical Preparations for Dianthus Therapeutics.